Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163711 | 0.81 | KDR (0.48) | KDRHPGDBRAFRAF1EPHX2 | |
| SCHEMBL3257638 | 0.79 | KDR (0.47) | KDRHPGDBRAFRAF1EPHX2 | |
| SCHEMBL171083 | 0.79 | CTSA (0.48) | KDRBRAFRAF1NPC1PKM | |
| SCHEMBL29580736 | 0.79 | CTSA (0.48) | KDRBRAFRAF1NPC1PKM | |
| SCHEMBL30201887 | 0.79 | KDR (0.47) | KDRHPGDBRAFRAF1EPHX2 | |
| SCHEMBL2642554 | 0.79 | KDR (0.47) | KDRHPGDBRAFRAF1EPHX2 | |
| SCHEMBL2643035 | 0.79 | ALDH1A1 (0.50) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL131789 | 0.78 | ALDH1A1 (0.50) | HPGDPARP1KDM4EALDH1A1LMNA | |
| SCHEMBL2642557 | 0.78 | KDR (0.46) | KDRHPGDBRAFRAF1EPHX2 | |
| SCHEMBL2642839 | 0.78 | KDR (0.46) | KDRHPGDBRAFRAF1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104105694-A | Amide compound and use thereof for pest control | SUMITOMO CHEMICAL CO | 2014-10-15 | — | — | CN | disclosed |
| US-8765789-B2 | 2-pyridinecarboxamide derivatives | MSD K.K. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| CN-100422172-C | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-100374435-C | Substituted pyridazines having angiogenesis inhibiting activity | BAYER CORP (US) | 2008-03-12 | — | — | CN | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| CN-1769283-A | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| CN-1769282-A | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| CN-1420879-A | Substituted pyridines and pyridazines having angiogenesis inhibiting activity | BAYER AG (US) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | KDR 1487/4885HPGD 2127/4885BRAF 1215/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | KDR 1492/4885HPGD 2159/4885BRAF 1195/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | KDR 1487/4885HPGD 2127/4885BRAF 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.